About QLine Biotech IPO
QLine Biotech Limited is set to launch its IPO under the SME IPO segment and is offering a book-built issue worth Rs. 214.48 crore. The company is in the diagnostics and in-vitro diagnostics (IVD) segment and is involved in the development, manufacturing, marketing, importing, and distribution of diagnostic consumables, reagents, kits, diagnostic devices, and diagnostic equipment used in various healthcare establishments.
Incorporated in 2013, the company has established itself in the Indian diagnostic healthcare market through the supply of IVD products and pathology equipment to diagnostic laboratories, hospitals, medical colleges, and healthcare service providers using both direct sales and distributor sales.
The primary business undertakings of QLine Biotech focuses on the local manufacture of diagnostic reagents that comprise Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and other rapid testing and POC diagnostic solutions. The company, in addition to manufacturing reagents, also undertakes manufacturing and supply of pathology and in-vitro diagnostic equipment that cater to various diagnostic healthcare needs.
QLine Biotech IPO Dates & Price Band
The QLine Biotech Limited IPO will open for subscription on 21 May 2026 and will be closed on 25 May 2026. Investors can expect to see their IPO allotment status on 26 May 2026 with refunds and shares being credited on 27 May 2026.
This SME IPO comprises a completely fresh issue with no offer for sale (OFS) of about 0.63 crore units. The company is looking to raise about Rs. 214.48 crore through this public issue.
The expected date for the QLine Biotech IPO to be listed is 29 May 2026 with the shares expected to be posted on the NSE SME.
The IPO price band has been set at Rs. 326 to Rs. 343 per share.
IPO Timetable (Tentative)
Click to open free demat account and apply for the IPO.
Company Financials
(Amount in Cr)
Cash Flows
(Amount in lac)
Revenue Bifurcation
(Rs. in Lac)
(Source: RHP)
QLine Biotech IPO Objectives
QLine Biotech plans to use the net proceeds raised from the IPO to meet several business and financial objectives to enhance operational and financial stability.
Around Rs. 93.50 crore of the proceeds from the IPO will be spent on the company’s working capital requirements. This investment will cover the daily operational expenditures of the company, working capital for inventory, the expansion of the supply of the company’s diagnostic products, and working capital to improve operational efficiency.
The company plans to use nearly Rs. 90 crore of the IPO proceeds to partially or fully repay or prepay some of the company’s borrowing. The company’s financial stability will be improved, the financial burden of interest payments will reduce, and the company will have more control over its financial position in the long term, as the company’s financial obligations will reduce.
Apart from the purposes listed above, the remaining funds may be used for the company’s continuous changing financial needs as corporate goals align, including business expansion, administrative expenses, and strategic business opportunities.
QLine Biotech IPO Peer Comparison
As per the Red Herring Prospectus (RHP), QLine Biotech Limited does, at present, have a competitor whose business operations fall within the same industry and business segment. The company provides health diagnostic solutions and the company manufactures and supply in-vitro diagnostics (IVD), reagents, pathology equipment, and point of care diagnostics.
As no other company with the same business structure and similar operational framework is listed, no traditional methods for peer to peer valuation comparison for the QLine Biotech IPO are available to the investors.
Market participants typically evaluate IPOs by taking into account things like revenue growth, profitability, product portfolio, and industry demand and considering the company’s future expansion plans and overall financial performance.
Valuation
QLine Biotech IPO Valuation
For FY 2025, QLine Biotech Limited reported an EPS (Earnings Per Share) of Rs. 28.63. If we consider the upper price band of Rs. 343, then the IPO is priced at a P/E ratio of around 11.98.
Q-Line Biotech Limited
Performance valuation results in estimating the price of the stock, investors will pay for a company’s profits. It means investors will consider profitability and also the growth potential of the company along with how much the investors consider the future potential of the firm’s products, and the unmet needs in Diagnostic Healthcare Solutions, before making their decision to buy this stock.
Strengths of Q-Line Biotech
Established manufacturing capabilities with focus on quality and R&D
QLine Biotech Limited has equipped itself very well to serve the diagnostic healthcare segment with manufacturing capabilities and quality control, research & development, and reverse engineering. The company’s focus on making diagnostic reagents and healthcare consumables locally will likely translate to customer value, operational productivity, and growth of the business.
Diversified product portfolio in the IVD segment
In the in-vitro diagnostics (IVD) domain, the company has a broad product range in Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and also rapid test kits and point of care diagnostics.
Strong distribution network across India
QLine Biotech has built a strong distribution network in the four regions of India.
The company is likely to improve product availability, enhance customer acquisition, and optimize its presence in the growing diagnostics market if it manages to strengthen its distribution network.
Long-term customer relationships
The Company has developed and nurtured long-term relationships with diagnostic service providers, hospitals, medical colleges, and distributors. Relationships that encourage return customers help to establish credibility in the market and generate revenue.
Risks of QLine Biotech IPO
Regulatory and compliance risk
QLine Biotech Limited is a company operating in the healthcare and diagnostics sector, which is densely packed with regulations. Changes to government regulations regarding compliance and product approvals or health care policy can affect the company, its products, and its operations. Regulatory compliance is always a must for the company to avoid penalties, operational restrictions, or reputational damage.
Biomedical and product accuracy risk
The company operates with diagnostic reagents and IVD products, along with pathology equipment, where product accuracy and reliability are of utmost importance. Problems in diagnostic accuracy or testing reliability, or problems with product performance can erode customer trust, and result in product recalls, legal action, and erode business prospects.
Quality control and manufacturing risk
The company relies on diagnostic consumables and health care products. Disruptions in manufacturing, quality control, and the supply chain, along with product defects, can adversely affect the reputation and the operational and financial performance of the company.
QLine Biotech IPO GMP Today
The QLine Biotech Limited IPO GMP is pegged at Rs. 127 as of 23 May 2026.
The QLine Biotech IPO is expected to list at around Rs. 486 per share, based on a maximum price of Rs. 343 per share.
Recent grey market premiums (GMPs) indicate that IPOs usually open with a 41.69% gain. The positive trend in GMP indicates good market sentiment before an IPO.
The QLine Biotech IPO GMP, expected listing price, and estimates of listing gain are important to potential investors as they indicate market demand. This is needed as the stock is yet to be listed on the NSE SME platform. It is worth noting that the QLine Biotech IPO GMP is unofficial and is expected to be highly volatile due to fluctuations in the market, subscriber behavior, and investor sentiment.
QLine Biotech IPO Lot Size
The minimum retail investor allotment for the QLine Biotech Limited IPO is 1 lot, equaling 400 shares. This means a maximum allowed allotment of 800 shares, equal to Rs. 2,74,400, per retail investor.
NII/HNI investors must apply for at least 3 lots, equaling 1,200 shares for a total investment of Rs. 4,11,600.
QLine Biotech IPO Allotment Status
If you wish to know the QLine Biotech IPO Allotment Status, please check the official Registrar’s site or the BSE site. Given below are the links for BSE sites.
BSE site - BSE IPO allotment status
Promoters And Management of QLine Biotech Ltd.
Saurabh Garg
Amita Garg
Ayush Garg
Ajay Kumar Mahanty
Abhay Agrawal
IPO Lead Managers
Hem Securities Ltd.
QLine Biotech Dividend History
QLine Biotech Limited has not paid or announced any dividends in the past three fiscal years. Instead of paying dividends to shareholders, the company invests profit into working capital within the diagnostic healthcare and IVD segments to expand and strengthen its business.
When looking into QLine Biotech dividend history or dividend payout, potential investors demonstrate this information to gauge the company’s capital allocation and the emphasis on long-term growth prior to capitalizing on the IPO.
QLine Biotech IPO Review
While reviewing QLine Biotech Limited IPO, potential investors will note that the diagnostic healthcare segment provides strong revenue growth, greater business scale, and ample positive EBITDA margins. The company’s long-term growth prospects within the healthcare diagnostic field can be supported by endogenous manufacturing, a growing distribution network, and a wide range of IVD products.
The company plans to use the funds obtained by the IPO for working capital and paying off debt. Either use will help QLine Biotech improve operational effectiveness and enhance the company’s financial standing.
QLine Biotech’s SME IPO will likely draw interest from nervous investors. Recently, the company has had negative cash flow from operations and increased debt. The diagnostic healthcare industry is a highly regulated environment that is sensitive to compliance issues and manufacturing quality. Non-adherence to product regulations could damage the goodwill of the company and ultimately affect the bottom line.
Most investors looking for QLine Biotech IPO reviews, analyses, GMPs, valuations, and expectations on the listing will consider growth potential and the risks related to an SME IPO prior to making an investment.
QLine Biotech DRHP
A Draft Red Herring Prospectus (DRHP) of QLine Biotech Ltd provides a detailed analysis of the company’s finances, operations, and risk factors. Potential investors can obtain information related to the company’s initial public offering (IPO) and invest if they desire.
QLine Biotech IPO DRHP Document Download
